MedTrace Logo

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

NCT05961956 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-12-24

No results posted yet for this study

Summary

Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.

Conditions

  • Degenerative Lumbar Spondylolisthesis

Interventions

DRUG

NVDX3

NVDX3 is implanted during a single surgical intervention.

Sponsors & Collaborators

  • Novadip Biosciences

    lead INDUSTRY

Principal Investigators

  • David BREUSKIN, MD · Centre Hospitalier du Luxembourg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-12
Primary Completion
2026-04-18
Completion
2026-04-18

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961956 on ClinicalTrials.gov